Skip to content

REtrospective Analysis on the Use of COvered Stents for the Treatment of the Dysfunctional Vascular Access

REtrospective Analysis on the Use of COvered Stents for the Treatment of the Dysfunctional Vascular Access

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04897828
Acronym
RECOVA
Enrollment
1000
Registered
2021-05-24
Start date
2021-06-01
Completion date
2021-12-31
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Study Focuses on the Use of Covered Stents (Stent Grafts) for the Treatment of Dysfunctional Vascular Access of Hemodialysis Patients

Keywords

covered stent, vascular access, dialysis, arteriovenous fitula, arteriovenous graft

Brief summary

This will be a multi-center, multi-national, investigator-initiated and lead, retrospective analysis assessing the safety and the clinical use of covered stents for the treatment of dysfunctional vascular access.

Detailed description

This will be a multi-center, multi-national, investigator initiated and lead retrospective analysis assessing the safety and the clinical use of covered stents for the treatment of the dysfunctional vascular access. There are no limitations on the type of covered stent use, the reason, or the length of the treatment area. The only limitations are the one owed to covered stent diameter and that patients included in the study should be treated for only one treatment area. The criteria for inclusion, the outcome measures and the variables that should be recorded are listed below. There is also no limitation if data has been previously published in another study, however data as part of an ongoing study, or of a study in press cannot be submitted. Due to previous experience from similar studies it is known that it will be difficult to have data available for all re-interventions. Thus, study will focus on primary patency and safety. Nevertheless, centers should provide data regarding circuit survival (thrombosis, abandonment, surgical revision, patient's death). Terms and definitions of outcome measures are provided below. Study's final follow-up date is March 31st, 2021. Patient should have a minimum follow-up of 6 months to be included in the study at that timepoint, unless circuit is no longer in use (thrombosis, abandonment, surgical revision, patient's death). If a scientific committee's approval is needed for the data collection, it is the center's responsibility to acquire it. If this is waived due to the nature of the study, this should also be stated. A large number of data will be recorded so hopefully, a lot of meaningful evidence will come up from this effort. As seen below, situations out of those allowed in the instructions for use for covered stents are included (ruptures, pseudoaneurysms, cannulation zone placement etc).

Interventions

DEVICECovered Stent placement

Covered stent placement for the treatment of dysfunctional vascular access of hemodialysis patients

Sponsors

University Hospital of Patras
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age \>18 years and \<80 years * Patient on Dialysis with an Arteriovenous Fistula (AVF) or Graft (AVG) * Clinical Signs of Vascular Access Dysfunction or presence of a Pseudoaneurysm or Intraprocedural Vessel Rupture * Use of Covered Stent(s) for treatment * Minimum follow-up: 6 months

Exclusion criteria

* \>1 treatment areas included per procedure * Covered Stent not available in the market any more

Design outcomes

Primary

MeasureTime frameDescription
Safety: Procedural Complications30 daysProcedure-related Minor Complications No therapy, no consequence Nominal therapy, no consequence; includes overnight admission for observation only Procedure-related Major Complications Require therapy, minor hospitalization (\<48 hours). Require major therapy, unplanned increase in level of care, Prolonged hospitalization (\>48 hours). Permanent adverse sequelae Death
Effectiveness: Clinically assessed intervention-free period of the treated segment6 monthsA dialysis access circuit with no need for clinically driven treatment area repeat intervention for symptom recurrence and angiographic verification of the presence of stenosis at the treatment area.

Secondary

MeasureTime frameDescription
Postintervention assisted primary patency12 monthsThe interval of patency after the endovascular intervention until dialysis circuit thrombosis or a surgical intervention of the access circuit. Endovascular interventions in a previously treated lesion and a new arterial or venous outflow stenosis or occlusion (excluding access thrombosis) are compatible with assisted primary patency. Assisted primary patency ends with percutaneous thrombolysis/thrombectomy or surgical circuit thrombectomy
Clinically assessed intervention-free period of the treated segment12 monthsA dialysis access circuit with no need for clinically driven treatment area repeat intervention for symptom recurrence and angiographic verification of the presence of stenosis at the treatment area.
Anatomic success12 monthsDefined as the resumption of normal hemodialysis for a minimum of at least 1 session following percutaneous intervention.
Access Circuit Primary Patency12 monthsThe interval of patency after an endovascular intervention until any repeat intervention of the access circuit.

Other

MeasureTime frameDescription
Exploratory analysis12 monthsfor identification of independent predictors influencing primary outcome measures.

Contacts

Primary ContactPanagiotis M Kitrou, MD, MSc, PhD, EBIR, FCIRSE
panoskitrou@gmail.com+306946686766

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026